GlassScriptPhysician profile
Arthur Galoustian
NPI 1487685426
$1,884.42
in general payments reported to CMS, 2019-2025
21 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $118 · 2021: $304 · 2022: $343 · 2023: $261 · 2024: $456 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.74 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $297.21 | 2020-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $264.16 | 2021-2024 | Benlysta |
| Amgen INC. | $242.66 | 2019-2023 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $172.75 | 2020-2025 | Jynarque |
| Novo Nordisk INC | $108.76 | 2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $100.32 | 2024 | |
| Ardelyx, INC. | $96.64 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $94.28 | 2019-2023 | Auryxia |
| Vifor Pharma, INC. | $73.48 | 2019-2024 | Korsuva, Veltassa |
| Calliditas Therapeutics US INC. | $71.15 | 2022-2024 | Tarpeyo |
| Scpharmaceuticals INC. | $57.59 | 2025 | |
| Novartis Pharmaceuticals Corporation | $51.77 | 2024 | |
| Fresenius USA Marketing, INC. | $50.41 | 2020-2023 | Velphoro |
| Alexion Pharmaceuticals, INC. | $44.63 | 2020-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $44.54 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.81 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $17.30 | 2020 | |
| Amicus Therapeutics, INC. | $15.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.94 | 2021 | |
| Lilly USA, LLC | $13.53 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Galoustian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.